NovalGen
NovalGen is a biotech company in Northwood Hills, United Kingdom, founded in 2019. It has 1 recorded funding round.
Breakthrough multi-specific antibody therapies
- Headquarters
- Northwood Hills, Middlesex
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- novalgen.com
- Rounds
- 1
Indexed holds 1 funding round and 1 investor for this company. The full record is or through the API.
About
NovalGen is a clinical-stage biotechnology company advancing breakthrough multi-specific biologics to transform outcomes in oncology, autoimmune, haematological, and metabolic disorders. The company uses its proprietary AutoRegulation platform to develop highly regulated biologics that offer safer and more potent therapeutic options for patients. Formed in 2019 from proprietary innovation at UCL, NovalGen focuses on next-generation multi-specific antibody therapies for cancer, autoimmune disease, and haematology.
Summary
It lists 11–50 employees. Investors include UCL Technology Fund.
Tech & App Stack
5 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Investors
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/novalgen"><img src="https://indexed.vc/api/badge/company/novalgen" alt="NovalGen on Indexed.vc" width="260" height="76" /></a>